At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NAUT Nautilus Biotechnolgy, Inc.
Not Yet Opened 12-22 16:00:00 EST
1.98
+0.04
+2.06%
盘后1.98
+0.000.00%
16:38 EST
High2.03Low1.93Vol167.77K
Open1.94D1 Closing1.94Amplitude5.02%
Mkt Cap250.08MTradable Cap91.63MTotal Shares126.31M
T/O332.97KT/O Rate0.36%Tradable Shares46.28M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Penny Stocks To Consider In December 2025
Simply Wall St.  ·  12-02
Penny Stocks To Consider In December 2025
Nautilus Biotechnology Chief Marketing Officer Kentaro Suzuki Acquires Common Shares
Reuters  ·  11-11
Nautilus Biotechnology Chief Marketing Officer Kentaro Suzuki Acquires Common Shares
Nautilus Biotechnology Regains Nasdaq Compliance After Transfer to Capital Market
Reuters  ·  11-04
Nautilus Biotechnology Regains Nasdaq Compliance After Transfer to Capital Market
Nautilus Biotechnology Unveils Reproducible Single-Molecule Proteomics Data at Buck Institute
Reuters  ·  11-03
Nautilus Biotechnology Unveils Reproducible Single-Molecule Proteomics Data at Buck Institute
Nautilus Biotechnology Faces Nasdaq Delisting Risk Amid Compliance Challenges
TIPRANKS  ·  10-30
Nautilus Biotechnology Faces Nasdaq Delisting Risk Amid Compliance Challenges
Nautilus Q3 2025 Earnings Call Summary and Q&A Highlights: Tau Assay Progress and Strategic Collaborations
Earnings Call  ·  10-29
Nautilus Q3 2025 Earnings Call Summary and Q&A Highlights: Tau Assay Progress and Strategic Collaborations
Nautilus (NAUT) Q3 2025 Earnings Call Transcript
Motley Fool Transcribing  ·  10-29
Nautilus (NAUT) Q3 2025 Earnings Call Transcript
Nautilus Biotechnolgy (NAUT) Gets a Buy from TD Cowen
TIPRANKS  ·  10-29
Nautilus Biotechnolgy (NAUT) Gets a Buy from TD Cowen
BRIEF-Nautilus Biotechnology Q3 EPS USD -0.11
Reuters  ·  10-28
BRIEF-Nautilus Biotechnology Q3 EPS USD -0.11
Nautilus Biotechnology Inc - Early Access Program With Tau Proteoforms Expected in H1 2026
THOMSON REUTERS  ·  10-28
Nautilus Biotechnology Inc - Early Access Program With Tau Proteoforms Expected in H1 2026
Nautilus Biotechnology Q3 Net Income USD -13.574 Million
THOMSON REUTERS  ·  10-28
Nautilus Biotechnology Q3 Net Income USD -13.574 Million
Nautilus Biotechnology Q3 Operating Expenses USD 15.472 Million
THOMSON REUTERS  ·  10-28
Nautilus Biotechnology Q3 Operating Expenses USD 15.472 Million
Press Release: Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
Dow Jones  ·  10-28
Press Release: Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
BRIEF-Nautilus Biotechnology Inc - Quarterly Net Loss Per Share $0.11 - Filing
Reuters  ·  10-28
BRIEF-Nautilus Biotechnology Inc - Quarterly Net Loss Per Share $0.11 - Filing
Nautilus Biotechnology Q3 EPS $(0.11) Beats $(0.15) Estimate. Cash And Equivalents Of $168.5M
Benzinga  ·  10-28
Nautilus Biotechnology Q3 EPS $(0.11) Beats $(0.15) Estimate. Cash And Equivalents Of $168.5M
Nautilus Biotechnology Inc - Expect to Launch Early Access Program With Tau Proteoforms in the First Half of 2026
THOMSON REUTERS  ·  10-28
Nautilus Biotechnology Inc - Expect to Launch Early Access Program With Tau Proteoforms in the First Half of 2026
Nautilus Biotechnology Inc - Qtrly Net Loss per Share $0.11 - Filing
THOMSON REUTERS  ·  10-28
Nautilus Biotechnology Inc - Qtrly Net Loss per Share $0.11 - Filing
Nautilus Biotechnology posts Q3 net loss of $13.6 million
Reuters  ·  10-28
Nautilus Biotechnology posts Q3 net loss of $13.6 million
Nautilus Biotechnology Inc expected to post a loss of 15 cents a share - Earnings Preview
Reuters  ·  10-24
Nautilus Biotechnology Inc expected to post a loss of 15 cents a share - Earnings Preview
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025
GlobeNewswire  ·  10-07
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025

Introduction

Company Name.
Nautilus Biotechnolgy, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was incorporated in 2016 and is headquartered in Seattle, Washington.
Issue price:
--